Tetrylammonium

Tetrylammonium

SCHEMBL6237150

CC(=O)N(O)CCc1cc2ccccc2s1.CC[N+](CC)(CC)CC

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.44
ADRB2 P07550 1/20 0.41
ASIC3 Q9UHC3 1/20 0.41
LOXL2 Q9Y4K0 1/20 0.41
NPY2R P49146 1/20 0.40
BCL2L1 Q07817 1/20 0.40
RAB9A P51151 1/20 0.40
AGXT P21549 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
OPRM1 P35372 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6344125 0.92 CYP2A6 (0.51) CYP2A6ADRB2ASIC3LOXL2BCL2L1
Ammonia Solution, Strong SCHEMBL6237737 0.91 CYP2A6 (0.50) CYP2A6ADRB2ASIC3LOXL2BCL2L1
SCHEMBL1445507 0.79 CYP2A6 (0.53) CYP2A6ADRB2ASIC3LOXL2BCL2L1
SCHEMBL436458 0.78 CYP2A6 (0.51) CYP2A6ADRB2ASIC3LOXL2BCL2L1
SCHEMBL1444702 0.78 CYP2A6 (0.45) CYP2A6ADRB2ASIC3LOXL2NPY2R
SCHEMBL1444257 0.75 CYP2A6 (0.45) CYP2A6ADRB2ASIC3LOXL2BCL2L1
SCHEMBL4847281 0.74 CYP2A6 (0.56) CYP2A6ADRB2ASIC3LOXL2NPY2R
Tetrylammonium SCHEMBL2399019 0.73 ALOX5 (0.64) ALOX5CYP1A2PTGESLMNALTA4H
SCHEMBL21400323 0.71 CYP2A6 (0.53) CYP2A6ADRB2ASIC3LOXL2BCL2L1
SCHEMBL6963172 0.70 CYP2A6 (0.60) CYP2A6ADRB2ASIC3LOXL2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005011613-A2 COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LIPOXYGENASE INHIBITOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE EPIGENESIS PHARMACEUTICALS LLC (US) 2005-02-10 WO disclosed